2,216.20
+0.15%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Emcure Pharmaceuticals
Its shares trade on NSE under the ticker EMCURE.NS. It has been listed since 10 July 2024. In the fiscal year to 31 March 2026, it reported revenue of ₹92.04bn and net income of ₹9.24bn. At that date it held total assets of ₹96.12bn and shareholders' equity of ₹49.50bn.
Emcure Pharmaceuticals Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Pune, Maharashtra. The company went IPO on 2024-07-10. Emcure Pharmaceuticals Ltd is an India-based pharmaceutical company. The firm is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas. The company offers a range of products and services under formulations, biologics, and Active Pharmaceutical Ingredients (APIs). The company focuses on various key therapeutic areas, such as gynecology, cardiology, anti-infective, diabetes, biologics, mRNA vaccines, and vitamin, minerals and nutrients. The company offers products in both, chronic and acute segments. The firm's subsidiary, Gennova Biopharmaceuticals Limited, is a biotechnology company dedicated to developing, producing, and commercializing bio-therapeutics to address life-threatening diseases across various indications. The company has developed two platforms: Mammalian and Microbial. Its key APIs consists of S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate, and Eribulin. The company operates approximately 13 manufacturing facilities.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jul 2024
- Employees
- 11,146
- Website
- emcure.com ↗
Leadership
Pay as last reported
- Mr. Berjis DesaiNon-Executive Chairman of the Board$10.6m
- Mr. Satish MehtaChief Executive Officer, Managing Director, Executive Director, since 2024₹218.6m
- Mr. Tajuddin ShaikhChief Financial Officer₹15.6m
- Mr. Chetan SharmaCompany Secretary, Compliance Officer₹4.1m
- Dr. Mukund GurjarWhole Time Director, since 2001₹55.2m
- Mr. Samit MehtaWhole Time Director, since 2022₹28.5m
- Mr. Sunil MehtaWhole Time Director, since 2013₹32.7m
- Mrs. Namita ThaparWhole Time Director, since 2014₹41.8m
- Dr. Shailesh AyyangarIndependent Director₹5.3m
- Mr. Vijay GokhaleIndependent Director₹2.3m
- Mr. Palamadai JayakumarIndependent Director₹3.2m
- Dr. Vidya YeravdekarIndependent Director₹1.8m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Emcure Pharmaceuticals Ltd employs 11,146 full-time employees in Pune, Maharashtra.
- The company develops and markets products in gynecology, cardiology, and anti-infective therapeutic areas.
- Gennova Biopharmaceuticals Limited focuses on bio-therapeutics for life-threatening diseases.
Weaknesses
- Emcure's IPO listing date is 10 July 2024, which is recent.
- The company's API portfolio includes S-Amlodipine and Dydrogesterone, which may face competition.
- Emcure's focus on chronic and acute segments may limit market diversification.
Opportunities
- Emcure's mRNA vaccine platform could expand into new therapeutic areas.
- The company's biologics segment offers growth potential in global markets.
- Gennova's Mammalian and Microbial platforms support innovative drug development.
Threats
- The pharmaceutical industry faces regulatory challenges in India and globally.
- Emcure's reliance on specific APIs like Ferric Carboxymaltose may pose supply risks.
- Competition in the biologics market could impact market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.